Almost every age group is at higher risk for serious flu complications. The major problem arising these days regarding the control of influenza disease is the development of resistance among the influenza viruses against the existing anti-viral drugs that are being recommended. Also, these antiviral drugs have a number of side effects. The main objective of the present paper is to explore riboswitches as a novel target for design of drugs for influenza virus in order to address the issues of resistance and side effects of present drugs. Riboswitches are present in the non-coding region of mRNA that sense changes in the cellular environment and directly mediate appropriate gene control responses. These riboswitches are primarily found in the 5' untranslated regions of messenger RNAs. In the present paper in-silico approach is proposed for the prediction of riboswitches for the strains of influenza virus, their binding sites and design of their inhibitors. Two riboswitches have been predicted for the three strains of influenza virus and five inhibitors have been identified for each of the two riboswitches by virtual screening. These inhibitors are found to be free from the side effects of antiviral agents and have remote chances of being resistant.
Influenza is a contagious disease affecting the respiratory tract, caused by Influenza viruses A, B, C mainly A, its symptoms can lead from mild to severe illness and at times can lead to death as compared to typical sneezing and stuffiness of common cold. The flu viruses spread mainly by droplets when people with the flu cough, sneeze or talk. These droplets mainly land in the mouths or noses of people who are in the vicinity [1] [2] [3] [4] [5] [6] [7] . Moreover, the flu may get spread over an area directly or indirectly.
Symptoms of Influenza are Fever, Cough, Sore throat, Runny nose, Muscle or body aches, Headaches, Fatigue and some people may have vomiting and diarrhea also 8, 9 . Centers for Disease Control and Prevention estimated that around 90% of seasonal flu related deaths and more than 60% of hospitalizations in the united states occur in people of 65 years of age and older because human immune system becomes weaker with age 10 . People suffering with asthma have swollen and sensitive airways, and when they experience symptoms of influenza, it can cause further inflammation of the airways and lungs, not only asthmatic patients but also people with neurological disorders 11 suffer badly with influenza. People suffering with chronic lung diseases, Blood disorders (such as sickle cell disease), Endocrine disorders (such as diabetes mellitus), Kidney disorders, Liver disorders, people with HIV or AIDS and heart disease are also at high risk for flu complications.
The major problem with the existing antiviral drugs is the development of resistance among the influenza viruses against these drugs. Earlier Adamantanes i.e. Amantadine and Rimantadine were given for influenza treatment, but it was observed that resistance among influenza a viruses increased so fast for Adamantanes that it became necessary to stop their use in the treatment. It was observed that Adamantane resistance increased from 0.4% during 1994-1995 to 12.3% during 2003-2004 12 . After this treatment Neuraminidase Inhibitors i.e. Oseltamivir or zanamivir that are the primary antiviral agents were recommended for the prevention and treatment of influenza viruses [13] [14] [15] . But later the development of resistance [16] [17] [18] [19] for these antiviral drugs was reported which states that oseltamivir-resistant seasonal influenza A viruses were isolated from nine (18%) out of 50 Japanese children during treatment 17, 20 . Zanamivir is not recommended for immune-compromised children 16, 21 . During the post marketing surveillance allergic reactions, facial edema, and swelling are also reported 22, 23 . Apart from the development of resistance, the antiviral drugs have number of side effects.
The major problem faced with vaccination i.e. flu shots is that it might have some of the common local adverse reactions that includes erythema (redness), induration (firmness), swelling, pain, and pruritus (itching) at the vaccination site; headache, myalgia (muscle ache), and malaise.
These issues of drugs resistance and side effects of existing drugs are of major concern for treatment of influenza virus and there thus there is a need to explore novel drugs targets and design new inhibitor for influenza virus. The riboswitches can be explored as new drug target for such infectious diseases.
Riboswitches are present in the noncoding region of mRNA that sense changes in the cellular environment and directly mediate appropriate gene control responses. These riboswitches are primarily found in the 5' untranslated regions of messenger RNAs. They are being divided into two parts-Evolutionary conserved sensor domain (an aptamer) which directly binds small molecules and an expression platform which undergoes structural changes in response to changes in aptamer 24 . Binding domains are highly conserved, even among divergent organisms. It is believed to have persisted through evolution. The Expression Platform Sequences vary widely among riboswitches, sequence even varies within a class. These parts of riboswitches in combination acts like the operon system which is based on the ON and OFF mechanism for the expression of the genes associated when the aptamer region is bound to the appropriate ligand to show the ligand's efficiency onto the specific riboswitch binding site.
The most common mechanisms of riboswitches include: (1) formation of the hairpin structure that leads to RNA polymerase stalling and premature transcription termination, (2) basepairing between Shine-Dalgarno and anti-ShineDalgarno sequence that blocks translation, and (3) changing the splice sites 25, 26 . Riboswitches as a novel drug target and identify its potential inhibitor for H1N1, H2N2 and H3N2 strains of influenza virus.
BioRelix Inc. is building a club of antiinfective drug treatments that target riboswitches, or stretches of messenger RNAs that control genes expression and mechanism essential to the survival of many disease-causing microbes. This strategy has applications in the elimination of pathogens that are resistant to currently available drugs. The flow chart of framework is given in Fig. 1 .
MATERIAL & METHODS

Identification of Gene Sequence for Riboswitch -
The whole genomes of H1N1, H2N2 and H3N2 Influenza virus are obtained from the National Center for Biotechnology Information (NCBI) Gene Bank in FASTA format. The viral genome is searched for riboswitch like sequences present in it by online program Riboswitch Explorer to identify Riboswitch like sequences 6 .
Human Nucleotide Database Search for Gene Sequence Similarity by BLAST
The viral riboswitch like gene sequences identified by RibEx are searched in the National Center for Biotechnology Information database for similar gene sequence present in Human (Homo Sapiens) genome by using Basic Linear Alignment Sequencing tool (BLAST).
Transcription of Gene Sequence to Corresponding Riboswitch like Element (RLE)
The gene sequences identified by online program RibEx for riboswitch like elements are transcripted to its corresponding riboswitch by using online "Transcription and Translation Tool".
Structure Prediction of Riboswitch
The 3-Dimensional structure of the riboswitch like elements is predicted by using online program iFoldRNA. iFoldRNA program performs interactive RNA folding simulations using discrete molecular dynamics simulations using coarsegrained structural RNA models to predict the 3D structure of the identified sequence of riboswitch like elements present in the genomes of H1N1, H2N2 and H3N2 Influenza virus.
Blind Docking (BD)
AutoDock based Blind docking technique is used to find out appropriate binding site present in the predicted riboswitch like structures of H1N1, H2N2 and H3N2 Influenza virus. In blind docking technique whole structure of riboswitch is covered under imaginary 3D grid box for docking. The coordinates of grid box used for blind docking technique for all the two identified riboswitches PRI1 and PRI2 are given in Table-1. 27,10,4,28
All computational studies are carried out using Autodock 4.2 installed on a single machine running on a 2.80 GHz Intel core2 duo processor with 3GB RAM and 320 GB hard disk with Windows XP as an operating system. Docking software's like "AutoDock Tools", "Autogrid" and "Autodock-4.2" were downloaded from the Scripps portal (http:// autodock.scripps.edu). AutoDock software explores the whole surface of riboswitch for binding of ligand in the riboswitch. Alanine (ALA) is used as a ligand in blind docking technique to identify binding sites present in all the two predicted riboswitches, as it is the neutral and simplest ligand out of possible 20 amino acids as substrate of a riboswitch. Appropriate binding sites present in the surface of the predicted riboswitches are identified on the basis of lowest binding energy in the range of -5 to -15 Kcal/Mol. The appropriate binding site present in the predicted riboswitches of influenza is used for identification of binding residues involved in binding of ligand. The identified binding residues present in the predicted riboswitches are further utilized for focused docking.
Focused Docking (FD) for Identification of Ligand
Focused grid box covering ligand as well as binding residues involved in binding of ligand, is prepared for focused docking targeting specific ligand binding site for all the two identified riboswitches of Influenza virus [29] [30] [31] . The coordinates containing the information about the size and position of grid box used in focused docking of all the two predicted influenza riboswitches are tabulated in Table- 2. These three grid boxes are further utilized for focused docking with 20 different amino acids for identification of specific substrate ligand for all the two predicted riboswitches.
Refinement of Docking Results
After identification of an appropriate ligand for predicted riboswitches by focused docking, separate docking of identified substrate ligand with its corresponding riboswitch is done for all the two riboswitches identified in the genome of Influenza virus repeatedly for a number of times to refine the results.
Virtual Screening Using NCI Diversity Set
The identified binding sites present in all the two predicted structures of novel Influenza riboswitches are utilized for virtual screening of NCI Diversity Set containing 1541 diverse molecules 32 . All the files necessary for virtual screening are prepared by software Raccoon. It is a graphical user interface for AutoDock virtual screening (autodock.scripps.edu/resources/ raccoon). Raccoon can split multiple-molecule ligand library files, convert them into the AutoDock format (i.e. *. pdbqt), and filter them by using common criteria (e.g., Lipinski's rules, fragmentlike "rule of 3", and drug-likeness). A validation check of the input files is performed at every step, which includes checking for the presence of nonstandard atom types and ensuring that parameters, input file names, and grid maps have a coherent format.
Molecular docking simulation based virtual screening of all the two influenza riboswitches is done using similar docking and grid parameters used in focused docking earlier.
The coordinates of the grid box used in the virtual screening process of molecular libraries containing 1880 molecules against the binding site of riboswitches are tabulated in Table- 3. The coordinates of grid box used in virtual screening of both the riboswitches PRI1 and PRI2 are given in Table-3 .
Evaluation of Physicochemical Properties of Lead Compounds
The top five screened ligands for each riboswitch are evaluated for important physicochemical properties such as calculated partition coefficient (ClogP), 2D-Polar surface area (2D PSA), molecular weight, hydrogen bond donor and acceptor sites etc. by using Marvin Sketch software.
Prediction of ADME & Toxicity of Lead Compounds
The top 5 lead molecules for both the two riboswitches are evaluated by using the OSIRIS online program for toxicity and ADME properties 33 . This program evaluates the presence of major toxicities such as mutagenicity, tumorigenicity, irritant effect and reproductive effects in the lead molecules on the basis of functional group present in their chemical structure. This program also calculates drug-likeness and drug score of the lead molecules on the basis of their physicochemical properties.
The results obtained in each of the above steps are presented in the next section.
RESULTS AND DISCUSSION
The stepwise results obtained are summarized and discussed below:
Identified Genes for Riboswitch like Sequence
The following two gene sequences are identified by the RibEx for transcription into riboswitch like elements present in the viral DNA of H1N1, H2N2 and H3N2 Influenza virus genome. PRI1-TATGAGGCCCATACAACTGGCAAGTG CACCAGCAGAATAA PRI2-ATCCCAAAATCCCCTTAGTCAGAGG Gene Sequence Similarity with Human Genome
The identified riboswitch like gene 
PRI1
The gene sequence of PRI1 riboswitch shows a BLAST score 38.2 with a maximum 97% of gene sequence similarity present in the human genome. The BLAST result of gene sequence similarity to PRI1 gene sequence is shown in Fig. 2(A) . The human genome showing 38.2 blast score is searched for the presence of any riboswitch like gene sequence by using RibEx software. No riboswitch was found in similar gene in the human genome
PRI2
The gene sequence of SPR1 riboswitch shows a BLAST score 34.2 with a maximum 72% gene sequence similarity present in the human genome. The BLAST result of gene sequence similarity to PRI2 gene sequence is shown in Fig 2(B) The identified two DNA gene sequences are transcripted to corresponding riboswitch like elements using online, "Transcription and Translation Tool". The tool replaces the thymine (T) nucleotide of the gene sequence with uracil (U) to form its corresponding riboswitch (mRNA).
Predicted tertiary Structures of Riboswitch
The tertiary structures of both the identified riboswitches in H1N1, H2N2 and H3N2 Influenza virus are predicted by online program iFoldRNA, and following results are obtained. (a)
The tertiary structure of Influenza riboswitch PRI1 is identified by using online program iFoldRNA. The PRI1 riboswitch consists of a single chain of 40 nucleotides. The predicted tertiary structure of PRI1 riboswitch in Influenza virus is shown in Fig. 3 .
The tertiary structure of the Influenza riboswitch PRI2 is identified by using online program iFoldRNA. The PRI2 riboswitch consists of a single chain of 25 nucleotides. The predicted tertiary structure of PRI2 riboswitch in Influenza bacteria is shown in Fig. 4 .
Blind and Focused Docking Results (a)
The binding site present in the Influenza riboswitch PRI1 identified by Blind docking suggests that the residues ADE34, ADE31
CYT33, GUA24 and GUA32 of PRI1 riboswitch are involved in the binding of ligand.
The focused docking of PRI1 riboswitch using the identified binding residues involved in the binding of the ligand with the riboswitch suggests the Lysine as its substrate ligand as it shows best binding among 20 amino acids with a binding energy value of -7.26 Kcal/Mol (Ki = 4.74 µM). The ligand binding site identified in predicted three dimensional structure of PRI1 riboswitch of Influenza virus is shown in Fig. 6 . The focused docking result of PRI1 riboswitch is tabulated in Table- 
The binding site present in the Influenza riboswitch PRI2 is identified by blind docking suggests that the residues CYT11, URI10, ADE21, GUA22 and ADE23 of PRI2 riboswitch are involved in the binding of ligand.
The focused docking of PRI2 riboswitch using the identified binding residues involved in the binding of the ligand with the riboswitch suggests the Tryptophan as its substrate ligand as it shows best binding among 20 amino acids with a binding energy value of -6.77 Kcal/Mol (Ki = 10.91µM). The ligand binding site identified in Fig.7 . The focused docking result of PRI2 riboswitch is tabulated in Table-5. Docking results obtained by blind docking of both the riboswitches i.e. PRI1 and PRI2 are tabulated in Table-6 .
Refined Docking Results
The results of individual docking of riboswitch PRI1 with Lysine for a repeated number of times are given in Table- 7. There was a change in its binding energy from -7.26 to -Kcal/Mol.
Similarly the Arginine is repetitively docked with PRI2 for refinement of their binding Table-7 .
Virtual Screening Results
The 5 lead molecules for each riboswitch were selected after virtual screening of NCI Diversity Set containing 1541 diverse molecules against all the three predicted Influenza riboswitches PRI1 and PRI2. The binding energy and Ki value of 5 lead molecules for both of the influenza riboswitches are given in Table-8 and 9 for each of the predicted riboswitch PRI1 and PRI2 respectively. (a)
The following five lead molecules were obtained for PRI1 riboswitch after the virtual screening: NCI_81462_a, NCI_168184, NCI_113486, NCI_207895 and NCI_3076_a. The binding energy and Ki value of top 5 lead molecules for PRI1 riboswitches is given in Table- 
The five lead molecules were obtained for PRI2 riboswitch after the virtual screening: NCI_117268_a, NCI_170621, NCI_281816_a, NCI_403379 and NCI_13316_b. The binding energy and Ki value of top 5 lead molecules for PRI1 riboswitches is given in Table-9 .
Physicochemical Properties of Screened Lead Compounds (a)
The physicochemical properties of screened top 5 lead molecules for PRI1 influenza riboswitch are tabulated in Table- The physicochemical properties of screened top 5 lead molecules for PRI2 Influenza riboswitch is tabulated in Table-11 .
ADME & Toxicity Profiling
The results of toxicity and ADME prediction of screened top 5 lead compounds for both the riboswitches is computed by using Osiris online program. (a)
The toxicity prediction and drug likeness score for top 5 virtually screened lead molecule for PRI1 riboswitch are shown in Fig. 7 to 11 . The three lead compounds out of top 5 screened leads ZINC19325791, ZINC19362650 and ZINC08652230 passed the toxicity test with a good drug likeness score, while lead ZINC01556940 shows satisfactory drug score but there is a probability of presence of some reproductive effects is shown in the toxicity test. The lead compound ZINC19230120 shows the poor drug likeness score and supposed to be having serious toxic effects such as mutagenicity, irritant nature and reproductive effects. (b)
The toxicity prediction and drug likeness score for top 5 virtually screened lead molecule for PRI2 riboswitch are shown in Fig. 12 to 16 . All the five screened lead compounds ZINC01584497, ZINC03947435, ZINC13597738, ZINC01729525 and ZINC01871223 passed the toxicity test without any toxic effect and satisfactory drug likeness score.
CONCLUSION
We have been able to perform in-silico prediction of two riboswitches for H1N1, H2N2 and H3N2 strains of Influenza A. The in-silico approach has further been successfully used to predict binding sites and specific ligands for these strains of influenza and lead molecules which inhibit these riboswitches. In all the three strains of influenza Lysine is found to be the most efficient ligand.
Thus, we conclude that in-silico approach can be used for prediction of riboswitches, their binding sites, specific ligands, and their potential inhibitors.
The inhibitors predicted are free from the side effects of the antiviral drugs and have remote chances of developing resistance. In all such studies can be useful for developing novel drugs for infectious disease like influenza. 
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